Abstract
On March 19, 2019, Brexanolone (Zulresso ™) was released as the first-ever FDA-approved medication specifically for the treatment of postpartum depression by Sage Therapeutics, Inc. Unfortunately, its use in breastfeeding mothers was not evaluated and is being restricted. An efficacious drug for postpartum depression stands to benefit many families. However, the lack of guidance for breastfeeding patients, and the resultant restrictions on breastfeeding by insurance companies is deeply troubling. Conversely, withholding this medication from a lactating mother is ethically problematic. From a public health perspective, we aim to foster continuous breastfeeding among depressed women while they are being treated for depression. We therefore aim to address concerns about Brexanolone’s effects on the breastfed child, as exposed through breastmilk, as well as the impact this medication may have on lactation.
This is a preview of subscription content, log in via an institution to check access.
References
Ahlqvist-Björkroth, S., Vaarno, J., Junttila, N., Pajulo, M., Räihä, H., Niinikoski, H., & Lagström, H. (2016). Initiation and exclusivity of breastfeeding: Association with mothers’ and fathers’ prenatal and postnatal depression and marital distress. Acta Obstetricia et Gynecologica Scandinavica, 95(4), 396–404. https://doi.org/10.1111/aogs.12857
BlueCross BlueShield of North Carolina (2019) Brexanolone Corporate Medical Policy. Retrieved November 11, 2019 https://www.bluecrossnc.com/sites/default/files/document/attachment/services/public/pdfs/medicalpolicy/brexanolone_zulresso.pdf
Dias, C. C., & Figueiredo, B. (2015). Breastfeeding and depression: A systematic review of the literature. Journal of Affective Disorders, 171, 142–154. https://doi.org/10.1016/j.jad.2014.09.022
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., Hoffmann, E., Rubinow, D., Jonas, J., Paul, S., & Meltzer-Brody, S. (2017). Brexanolone (SAGE-547 injection) in post-partum depression: A randomised controlled trial. The Lancet, 390(10093), 480–489. https://doi.org/10.1016/S0140-6736(17)31264-3
Luisi, S., Petraglia, F., Benedetto, C., Nappi, R. E., Bernardi, F., Fadalti, M., Reis, F. M., Luisi, M., & Genazzani, A. R. (2000). Serum allopregnanolone levels in pregnant women: Changes during pregnancy, at delivery, and in hypertensive patients. The Journal of Clinical Endocrinology & Metabolism., 85(7), 2429–2433
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., Jonas, J., & Kanes, S. (2018). Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet, 392(10152), 1058–1070. https://doi.org/10.1016/S0140-6736(18)31551-4.Erratum.In:Lancet.2018Sep29;392(10153):1116
National Library of Medicine (US). (2006). Drugs and lactation database (LactMed). National Library of Medicine (US). Retrieved January 23, 2020 from https://www.ncbi.nlm.nih.gov/books/NBK540687/
Sha, T., Gao, X., Chen, C., Li, L., Cheng, G., Wu, X., Tian, Q., Yang, F., He, Q., & Yan, Y. (2019). A prospective study of maternal postnatal depressive symptoms with infant-feeding practices in a Chinese birth cohort. BMC Pregnancy and Childbirth, 19(1), 388. https://doi.org/10.1186/s12884-019-2559-1
US Food and Drug Administration (2019) FDA approves first treatment for post-partum depression. Retrieved January 23, 2020, from https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression
Westerfield, K. L., Koenig, K., & Oh, R. (2018). Breastfeeding: Common questions and answers. American Family Physician, 98(6), 368–373
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rosen-Carole, C., Ito, S. Using Brexanolone for Postpartum Depression Must Account for Lactation. Matern Child Health J 25, 1007–1009 (2021). https://doi.org/10.1007/s10995-021-03144-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10995-021-03144-0